Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...

The acquisition will expand Lilly's oncology pipeline with STX-478 ... or that the acquisition will yield commercially successful products. For further discussion of these and other risks and ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...

Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year.

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

immunology and oncology. Some of these companies also make vaccines, animal health products, medical devices and consumer-related healthcare products. These players invest millions of dollars in ...

H.C. Wainwright analyst Robert Burns has reiterated their bullish stance on RLAY stock, giving a Buy rating yesterday.Stay Ahead of the ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...